PROCARDIS exploits advances in complex trait genetics and functional genomics to discover novel susceptibility genes for coronary artery disease (CAD). PROCARDIS is incorporating a definitive genome-wide association analysis, next generation sequencing and measurement of novel intermediate phenotypes to yield biomarkers for CAD risk and quantitative traits for genetic analysis.
- identify novel proteins and pathways implicated in atherosclerosis and arterial thrombosis
- define new targets for prevention and treatment
- devise diagnostic tools
Cardiovascular mortality and morbidity in Europe which represents 1/3 to 1/2 of overall mortality rates hardly needs to be underlined. Two well recognised general features characterise the cardiovascular mortality figures within Europe, of which CAD accounts for between 1/3 and 2/3: a great inter-country variability, with decreasing East-West and North-South gradients, and a falling prevalence in the Western and Southern countries contrasting the stable/increasing rates in many Eastern countries. The need for targeted studies with the aim of exploring the specific interaction between genetic and environmental risk factors is recognised as a priority.
The PROCARDIS project was funded with 10 million Euros through the 6th Framework Program of the European Union (LSH-2005-2.1.1-1). The project is aimed to integrate the efforts of key European basic and clinical scientists into one cohesive effort. It started in Apr 2007 and funding lasted till Sept 2011. After the funding ended, PROCARDIS is still actively doing research in the field of coronary artery disease genetics. For more details, see our publications page.
[Previous web address of this website was www.procardis.org.]